Drug company manager: Our newest product is just not selling. ███ ███ ██ ████ ██ █████ ██ █ ███ █████████ █████████ ████ █████ ███ █████████ ████████ ███ ██ ██ ███ ██████ ██ ████ ███ ████████ ██ ██ ██████ ███ ███
The drug company manager's conclusion is the recommendation or value judgment at the end of the stimulus: the company should try a new marketing campaign. The only premise offered in support of this conclusion--in other words, the only reason given for why the company should try a new campaign--comes immmediately before. Even though it's not guaranteed to work, the marketing campaign is one chance at saving the product.
The argument jumps from "a new marketing campaign is one chance at success" to "we should try a new marketing campaign". This assumes that something being "one chance" at success is a sufficient reason for it to be tried, regardless of how likely it is to actually work, or whether there are other strategies that might be more likely to succeed. This also assumes that saving the product is something the company should do, rather than abandoning the product.
Which one of the following, ██ █████ ████ █████████ ███████ ███ █████████ █████████
The drug company ███ ████████ ███████ ██ ███ ██████ ████████ ███ ██████ ███ ██ ████ ███████ █████ ██ ███████ ██ ███ █████████ ████████
Many new products ████ ███████ ██ ███ ████ ███ █████████ ██ █████████ ██████████
The drug company ██████ ███ █████████ █ ███ █████████ ████████ ███ ███ ██████ ███████ ██ ███ ████████ ███ ██ ██████ ██ ████████
Undertaking a new █████████ ████████ █████ ████████ ███ ████ █████████ ███████ ████████ ██ █████████████ ████████ ██ ████████ █████████ ██████████
Consumer demand for ███ ████ █████████ █████ ████████ ███ ████ ██████ ██ ███ ████ █████ ███ █████████ ██████ ███████ ███ ███████████